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Abstract
The retinoblastoma tumor suppressor (pRb) has tradi-
tionally been studied as a negative regulator of cell
cycle progression through its interactions with the
E2F family of transcription factors. Utilizing prostate
epithelial cell lines established from Rb+/+ and Rb/
prostate tissues, we previously demonstrated that
Rb/ epithelial cells were not transformed and
retained the ability to differentiate in vivo despite the
lack of pRb. To further study the effects of pRb loss in
an epithelial cell population, we utilized oligonucleo-
tide microarrays to identify any pRb-dependent tran-
scriptional regulation during serum depletion–
induced growth arrest. These studies identified 120
unique transcripts regulated by growth arrest in Rb+/+
cells. In these wild-type cells, the majority (80%) of
altered transcripts were downregulated, including 40
previously identified E2F target genes. Although the
transcriptional repression of E2F target genes is
characteristic of pRb pocket protein family activity,
further analysis revealed that, compared to Rb+/+ cells,
Rb/ cells exhibited a nearly identical response for all
transcripts including those of E2F target genes. These
findings demonstrate that pRb is not strictly required
for the vast majority of transcriptional alterations
associated with growth arrest.
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Introduction
Inactivation of the Rb gene has been implicated in the
development of many human cancers, including prostate
cancer [1]. The protein product (pRb) of this gene is a nuclear
phosphoprotein associated with G1/S phase cell cycle tran-
sition [2–4], cellular differentiation [5,6], senescence [7], and
apoptosis [8,9]. The molecular mechanism underlying pRb
function appears to be considerably complex as pRb interacts
with a medley of cellular proteins (see Ref. [10] for a review).
Despite these many diverse interactions, pRb has tradition-
ally been viewed as a repressor of E2F transcription factors
and thereby a transducer of growth-inhibitory signals that
result in a G1 phase growth arrest.
The E2F transcription factor family consists of seven pro-
teins (E2Fs 1–7) and their heterodimeric binding partners DP1
and DP2 (see Ref. [11] for review). E2Fs 1–5 contain con-
served transactivation and Rb pocket protein interaction
domains; however, despite this fact, E2F4 and E2F5 primarily
exhibit features of transcriptional repressors being found pre-
dominantly in complex with pocket proteins and chromatin-
modifying enzymes during G0/G1 when E2F target genes are
repressed [12]. E2Fs 1–3, on the other hand, are effective
transcriptional activators [13–15]. Through an intricate inter-
play of cell cycle–regulated activation and repression, the E2F
family mediates the transcription of an extensive list of genes,
many of which are required for DNA replication and cell cycle
progression (i.e., cyclin E, Cdc2, DNA Pol A2, and topoisomer-
ase 2A). Recently, microarray studies have delineated addi-
tional roles for E2Fs in the regulation of many genes involved in
other phases of the cell cycle (i.e., G2/M) [16,17].
Regulation of E2F activity is not only maintained by pRb, but
also by the other pocket protein family members p107 and
p130. The three pocket protein family members share a
common pocket domain that interacts with proteins containing
an LXCXE recognition motif [10]. Despite their similarity, the
different pocket proteins exhibit specificity in their binding to
various E2F family members. In general, the activating E2Fs
(E2Fs 1–3) are principally regulated by pRb, E2F5 is bound by
p130, and E2F4 can be found interacting with pRb, p107, or
p130 [18]. E2F6 and E2F7 do not contain the pocket protein
interaction domain and have not been shown to bind any of the
pocket proteins [19].
Although pocket protein function has been studied through
multiple approaches, homologous recombination at individual
pocket protein loci has provided significant insights into pRb,
p107, and p130 function. To date, knockout studies have been
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performed for the Rb1, Rbl1 (p107), and Rbl2 (p130) loci,
both individually and in a wide variety of combinations in mice
[20–27]. Homozygous inactivation of Rb led to embryonic
lethality at E13.5 due to defects in the central nervous system
and erythropoiesis. However, studies with chimeric mice and
heterozygotes (Rb+/) suggested that pRb is only necessary
for the development of specific cell lineages and promotes
tumors only in the pituitary and thyroid glands following loss
of heterozygosity of the wild-type Rb allele [21,25,27,28].
Mice lacking either p107 or p130 did not exhibit overt phe-
notypes [22,24]. However, combinatorial deletions of pocket
proteins (p107/Rb/, p130/Rb/, or p107/ p130/)
resulted in earlier embryonic lethality than the single Rb/
mutant and an overall increased severity of phenotypes,
suggesting that compensation may occur among the pocket
protein family members when one of the three members is
absent [24,26,29]. Studies with murine embryonic fibroblasts
(MEFs) generated from these knockout animals also sug-
gested the existence of compensatory mechanisms. Loss of
pRb, p107, or p130 alone failed to cause major differences in
cell cycle profiles of these cultures compared to wild-type
MEFs [30–32]. However, a triple knockout of pRb, p107,
and p130 together evoked convincing loss of G1 growth arrest
function and immortalization [31,32].
Until recently, studies with Rb/ samples have been pri-
marily limited to MEFs due to the early embryonic lethality of
theRbmutation. To study the effect of homozygous loss ofRb
in a mature tissue, Wang et al. [33] rescued viable urogenital
tissue fromE11Rb/ embryos through implantation of pelvic
visceral rudiments into nude mice followed by tissue recom-
bination with rat urogenital mesenchyme for continued ex-
pansion of these tissues. Consistent with the role of pRb as a
tumor suppressor, prostate tissue lacking pRb exhibited
significantly increased sensitivity to estradiol and testosterone-
induced tumorigenesis compared to wild-type tissues [33].
Recently, we have generated Rb/ prostate epithelial
cell lines (termed Rb/PrE) from Rb/ prostatic tissues
rescued by tissue recombination [34]. Although these Rb/
prostate epithelial cells have the ability to survive for extend-
ed periods of time under low-serum conditions, they remain
capable of inducing a G1 growth arrest when grown
to confluence. Therefore, we hypothesized that although
Rb/PrE exhibited considerable similarity to wild-type pros-
tate epithelial cells (wtPrE) in several regards, differences
that distinguish Rb/PrE from wtPrE may exist at the
molecular level. To assess the gene expression profiles of
Rb+/+ and Rb/ prostate epithelial cells, we have utilized
microarray analysis in an attempt to identify critical differ-
ences that exist between cells of these two genotypes.
Materials and Methods
Cell Culture and Treatments
wtPrE (Rb+/+) and Rb/PrE prostate epithelial cell lines
have been previously described [34]. Both cell lines were
maintained in RPMI 1640 supplemented with 5% fetal bovine
serum (FBS; Hyclone, Logan, UT), 2 mM L-glutamine, and
penicillin/streptomycin. For cell cycle analyses, cell lines
were plated into 100-mm dishes and allowed to adhere for
24 hours. Cells were then washed once with phosphate-
buffered saline (PBS) prior to the addition of RPMI 1640 with
no serum supplement. Twenty-four or 48 hours posttreat-
ment, cells were harvested for viable cell counts with trypan
blue, cell cycle analysis, or RNA/protein isolation as de-
scribed below.
Flow Cytometry
A total of 1  106 wtPrE or Rb/PrE cells was grown in
the presence or absence of serum for 48 hours, as described
above. Following treatment, cells were harvested by trypsi-
nization and fixed with 80% ethanol in PBS for 1 hour on ice.
Cells were then rehydrated in PBS for 15minutes and stained
with 1 mg/ml 4V,6-diamidino-2-phenylindole (DAPI) dihydro-
chloride (Molecular Probes, Eugene, OR) for 15 minutes
at room temperature. DAPI-stained cells were then de-
tected on a FACSVantage SE Model 127 (BD Biosciences,
San Jose, CA) and analyzed for cell cycle distribution
with the MultiCycle software (Phoenix Flow Systems, San
Diego, CA) by the University of Michigan’s Flow Cytometry
Core facility.
Western Blot Analysis
wtPrE and Rb/PrE cells were harvested by mechanical
disruption with cell scrapers followed by gentle centrifuga-
tion. Cell pellets were then lysed in appropriate volumes of
lysis buffer [50 mM Tris (pH 8.0), 120 mM NaCl, 0.5%
Nonidet P-40, 1 mM EGTA, 100 mg/ml phenylmethanesul-
fonyl fluoride, 50 mg/ml aprotinin, 50 mg/ml leupeptin, and
1.0 mM sodium orthovanidate] for 1 hour on ice. Cellular de-
bris was then removed by centrifugation, and supernatants
were collected and quantitated using a Bradford protein
assay (BioRad). Equal amounts of protein were then sepa-
rated on precast Tris–glycine SDS polyacrylamide gels
(Invitrogen, Carlsbad, CA) and transferred to Hybond
nitrocellulose membrane (Amersham Pharmacia Biotech,
Piscataway, NJ). Membranes were blocked for 1 hour at
room temperature in TBST [10 mM Tris (pH 8.0), 250 mM
NaCl, 0.1% Tween 20] containing 10% nonfat dry milk before
being probed overnight at 4jCwith primary antibodies diluted
in 2.5% milk/TBST. Following three washes in 2.5% milk/
TBST, membranes were incubated for 1 hour at room temper-
ature with appropriate horseradish peroxidase–conjugated
secondary antibodies. Following a second set of three washes
in 2.5% milk/TBST, membranes were developed with ECL
detection reagents (Amersham Pharmacia Biotech). Primary
antibodies were obtained as follows: pRb (no. 554136; Phar-
mingen, San Diego, CA), p107 (sc-318; Santa Cruz Biotech-
nology, Santa Cruz, CA), and p130 (R27020; Transduction
Laboratories, Lexington, KY).
RNA Isolation and Semiquantitative Reverse Transcription
Polymerase Chain Reaction (RT-PCR)
Total RNA was isolated from 3  106 cells utilizing
Qiagen’s RNeasy Mini kit. Following quantification, 2 mg of
total RNA was combined with 2.5 mM oligo (dT)20 primers,
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cDNA synthesis buffer (Invitrogen), 5 mM DTT, 40 U of
RNase OUT (Invitrogen), 1 mM dNTP mix, and 15 U of
Thermoscript Reverse Transcriptase (Invitrogen) to reverse-
transcribe mRNA for 1 hour at 55jC. Total cDNA was then
utilized in standard PCR reactions with gene-specific pri-
mers. To ensure that samples were within the linear range of
amplification when analyzed, aliquots were removed from
each reaction following PCR cycles 25, 28, 31, and 34, and
electrophoresed on 1.2% agarose gels containing ethidium
bromide. A 59jC annealing temperature was utilized for all
PCR reactions. Primers for each gene are as follows: actin:
forward 5V-gctcttttccagccttcctt-3V/reverse 5V-tgatcca-
catctgctggaag-3V; Ccnb1rs1: forward 5V-ggttgataatccctctc-
caagc-3V/reverse 5V-cattcttagccaggtgctgc-3V; Cdc2a:
forward 5V-ccgtcgtaacctgttgagtaac-3V/reverse 5V-gacaggaa-
gagagccaacgg-3V; Cdc25c: forward 5V-gccttgacctttcgaatct-
tag-3V/reverse 5V-cagaggaacacaatgatgactc-3V; c-Fos:
forward 5V-ccaagtgccggaatcggagg-3V/reverse 5V-gcttcaggg-
taggtgaagaca-3 V; c-Myb: forward 5 V-c tataacgac-
gaagaccctgag-3V/reverse 5V-gaatggtgtgggagttcgag-3V;
Cycb2: forward 5V-gacgtatgcgtgccatcctg-3V/reverse 5V-
cttcaggagtctgctgctggc-3V; DNA primase p46: forward
5V-gatgacgtaaggagatgctgc-3V/reverse 5V-cgataggcaca-
gaaatccgac-3V; Fen1: forward 5V-gagtctgtggagctgaagtgg-3V/
reverse 5V-cacttggaggcacaggtcag-3V; follistatin: forward 5V-
gttccaacatcacctggaagg-3V/reverse 5V-ggaaagctgtagtcctggtc-
3V; HPRT: forward 5V-cagtacagccccaaaatggt-3V/reverse
5V-ttactaggcagatggccaca-3V; Ifi203: forward 5V-gcctcca-
gaatcctcataagtc-3V/reverse 5V-ctgacattggtgagtcgtcca-3V;
Ki67: forward 5V-gaagggcactctccgctcag-3V/reverse 5V-
ggttggttcctcctgccagt-3V; Mcmd: forward 5V-gaccaaggcatttac-
cagaac-3V/reverse 5V-attgatgtctccacggatgtg-3V; Nupr1:
forward 5 V- g agga t g aaga t g gaa t c c t g g - 3 V/ r e v e r s e
5 V-ctgcttcttgctcccatcttg-3 V; Plk1: forward 5 V-gtatg-
tacgggggcgctttc-3V/reverse 5V-gtcacacagctgatacccaag-3V;
proliferin: forward 5V-ccatgtgtgcaatgaggaatgg-3V/reverse
5V-gtctaggcagctgatcatgcc-3V; Rrm2: forward 5V-cgccgagctg-
gaaagtaaag-3V/reverse 5V-gacaattcatggtgtagccag-3V; tenas-
cin C: forward 5V-cagccattgccactgtggacag-3V/reverse
5V-gtctccaaacccagcagcatag-3V; and thymidylate synthase:
forward 5V-gcaggcacgatacagcctgag-3V/reverse 5V-cact-
gaaagcactctaaacagc-3V.
Microarray and Data Analysis
Total RNA from wtPrE and Rb/PrE cells cultured in the
presence or absence of 5% FBS for 48 hours was obtained
with Qiagen’s RNeasy Mini kit according to the manufac-
turer’s protocol. Two 100-mm culture dishes of each cell line
were pooled to generate each sample and each condition
was analyzed by microarray analysis a minimum of two
times (nine arrays total: 3 wtPrE + serum, 2 wtPrE  serum,
2 Rb/PrE + serum, and 2 Rb/PrE  serum). RNA
quantity and quality were assessed with Agilent (Palo Alto,
CA) RNA 6000 Nano Eukaryote total RNA LabChips run on
an Agilent 2100 BioAnalyzer at the University of Michigan’s
Cancer Center DNA Microarray Core facility. Fragmented
biotin-labeled complementary RNA was generated from
10 mg of total RNA and hybridized to Affymetrix (Santa Clara,
CA) Murine Genome U74Av2 Arrays according to the man-
ufacturer’s suggested protocol at the University of Michigan’s
Cancer Center DNA Microarray Core facility. These
Affymetrix GeneChips are capable of measuring the expres-
sion levels of 12,422 sequences including f6000 function-
ally characterized sequences from the mouse UniGene
database (build 74) and f6000 expressed sequence tag
clusters. Arrays were scanned with an Affymetrix GeneChip
Scanner and the resulting .cel files were analyzed with dChip
(www.dchip.org) to generate expression values for each
probe set and 90% confidence intervals for sample compar-
isons. Probe sets with expression values V50 were not
considered to be significantly above background signal and
were therefore not considered further. Probe sets exhibiting
a z2.0 lower bound of the fold change confidence interval
following serum withdrawal were considered to be signifi-
cant. Microarray data are available online at NCBI Gene
Expression Omnibus (http://www. ncbi.nlm.nih.gov/geo/) ac-
cession no. GSE934.
Results
Rb/PrE Cells Retain the Ability to Perform Growth Arrest
Under Serum-Depleted Conditions
Transduction of growth-inhibitory signals, which result in
growth arrest in the G1 phase of the cell cycle, is believed to
be the primary role of pRb [35]. To investigate the role of pRb
in the regulation of serum withdrawal– induced growth arrest,
we employed murine epithelial cell lines established from
Rb+/+ or Rb/ prostate tissues [34]. We have previously
confirmed the genotypes of all cell lines utilized in this study
by PCR and Western blot analysis [34].
As expected, the proliferation rates of wtPrE and
Rb/PrE were identical under log-phase growth conditions
in the presence of serum when pRb was inactivated by cyclin
dependent kinase–mediated phosphorylation (Figure 1A).
When serum was removed from the culture media, Rb+/+
cells growth-arrested rapidly with minimal increase in cell
number after 24 and 48 hours. Surprisingly, the growth rate
of Rb/ cell lines was also dramatically decreased when
serum was removed from cultures for the same period of
time (Figure 1A). To examine the cell cycle distribution of
wtPrE and Rb/PrE under these short-term serum-free
culture conditions, cells were stained with DAPI as a mea-
sure of DNA content and subjected to flow cytometry. In
agreement with the aforementioned growth kinetics data, cell
cycle analysis revealed very similar profiles for both wild-type
and knockout cell lines (Figure 1B). When serum was
removed from the culture media, both cell lines exhibited
consistent 10% to 15% increases in G1 phase populations
and corresponding 10% to 15% decreases in S phase
populations (Figure 1B).
Considering the surprising similarity between the growth
kinetics and cell cycle profiles of Rb+/+ and Rb/ prostate
cell lines, we examined the response of the pocket protein
family members, pRb, p107, and p130, in both cell lines
following serum depletion. As expected, pRb transitions from
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a hyperphosphorylated inactive state to a dephosphorylated
active state over a 48-hour period of serum-free culture
(Figure 1C). Consistent with previous findings [34,36], wtPrE
cells exhibited decreased levels and potent dephosphoryla-
tion of p107, but increased levels of p130 following serum
withdrawal. Although the Rb/PrE cells did not express
detectable levels of pRb due to the insertion of stop codons
in the third exon of the Rb1 gene [21], they continue to
express p107 and p130. These two pocket proteins exhibited
identical growth arrest– induced changes as those observed
in the pRb-containing wtPrE cells (Figure 1C). Levels of p107
protein were approximately two-fold higher in Rb/ com-
pared to Rb+/+ cells. Taken together, these findings suggest
that similar growth arrest mechanisms exist in both cell lines
independent of Rb gene and protein status.
The Loss of pRb Does Not Alter the Transcription of Cell
Cycle–Regulated Genes
The most prominently studied mechanism by which
pRb regulates cell cycle arrest is regulation of transcription
through interaction with the E2F family of transcription fac-
tors. Therefore, a global inspection of gene expression
alterations induced by serum depletion and growth arrest
was performed with 12.4K Affymetrix GeneChip arrays.
Wild-type and Rb/PrE cells were cultured for 48 hours in
the presence or absence of 5% FBS prior to RNA extraction.
This timepoint was selected as pRb and p107 were f50%
dephosphorylated after 24 hours and nearly 100% dephos-
phorylated by 48 hours in wtPrE cells cultured in the absence
of serum. A minimum of two biologic replicates was per-
formed for each cell line/treatment combination (wtPrE +
serum, wtPrE  serum, Rb/PrE + serum, and Rb/PrE 
serum). Data from the scanned arrays were converted to
gene expression values, and 90% confidence intervals were
generated for growth-arrested versus control comparisons
with dChip software. Genes with a signal intensity z50 and a
lower bound of the confidence intervalz2.0 were considered
to be significant. These analytical criteria identified 120
unique affected transcripts, of which 24 (20%) transcripts
were reproducibly upregulated and 96 (80%) transcripts
were consistently downregulated during growth arrest in
wtPrE (Table 1).
Clustering of the genes based on the functional roles of
their protein products revealed that a large proportion of the
transcripts (38 of 85 genes with known function) was previ-
ously characterized as playing roles in cell cycle progression
or being cell cycle–regulated [37–39]. These genes included
many involved in DNA replication (e.g., Rrm2, Rrm1, Top2a,
Mcm3, Mcm5, and Pole2) and mitosis and cell division (e.g.,
Plk1, CycB1, CycB2, Rab6kifl, Kif8, Kif4, Cdc2a, and
Cdc25c). Additionally, several genes involved in the regula-
tion of transcription (e.g., c-Fos), chromatin structure (e.g.,
Ezh2), DNA repair (e.g., Rad51), and cytoskeletal structure
and adhesion (e.g., claudin 1 and tenascin C) were also
identified as being altered following serum depletion.
Interestingly, when the gene expression alterations in-
duced in wtPrE and Rb/PrE cells by serum depletion were
compared (Figure 2), patterns of repressed and activated
genes were highly conserved in the Rb/PrE cells despite
the absence of pRb. To quantify the similarity for each
transcript between the two cell lines, a ratio was generated
by dividing the average change in gene expression follow-
ing serum depletion observed in the wtPrE cell line by
the average change in gene expression observed in the
Rb/PrE cell line (Table 1). Of the 120 unique transcripts,
only 14 exhibited a z2.0-fold difference between the two cell
lines and, of these, only six transcripts exhibited a z2.5-fold
Figure 1. Growth kinetics and cell cycle analysis of wtPrE and Rb/PrE.
Rb+/+ and Rb/ cell lines were cultured in the presence or absence of 5%
FBS supplement and analyzed by (A) trypan blue staining to determine viable
cell number at 0, 24, and 48 hours; (B) DAPI staining to determine cell cycle
populations at 48 hours; and (C) Western blot analysis for pRb, p107, and
p130 at 0, 24, and 48 hours.
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Table 1. Comparison of Gene Expression Alterations in wtPrE and Rb/PrE Cells Following Serum Withdrawal.
Accession Locus
Link
Gene wtT/wtU* KOT/KOU Fold
Change
Repressed
by p16/pRby
Bound or
Regulated
by E2Fs
Cell
Cycle–
Regulated
Cell cycle – related (41 unique transcripts)
(A) DNA replication/chromosomal assembly/S phase progression (19 unique transcripts)
M14223 20135 Ribonucleotide reductase M2 (Rrm2)z 5.69 5.25 1.08 a,b c,d c
M12848 17863 Myeloblastosis oncogene (c-Myb)z 5.08 3.15 1.61
U01915 21973 Topoisomerase (DNA) II alpha (Top2a) 4.74 5.44 1.15 a c,d,f,g i
X62154 17215 Minichromosome maintenance–deficient
(Mcm3)z
4.27 1.62 2.64 a c,g c,i,j
AJ223087 23834 Cell division cycle 6 homolog (Cdc6) 3.73 5.00 1.34 g
X77731 13178 Deoxycytidine kinase (Dck) 3.58 2.63 1.36 b
AJ003132 27214 Activator of S phase kinase (Ask) 3.33 3.39 1.02 d,g
L26320 14156 Flap structure –specific endonuclease 1 (Fen1)z 3.11 2.33 1.33 a,b c,d,f,g c
AA929330 17215 Minichromosome maintenance–deficient
(Mcm3)z
2.95 1.66 1.78 a c,g c,i,j
D26090 17218 Minichromosome maintenance–deficient
5 (Mcm5)
2.9 2.02 1.44 a d,g c
K02927 20133 Ribonucleotide reductase M1 (Rrm1) 2.82 2.25 1.25 a,b d,g c
M33988 Histone H2A.1 (H2afa) 2.81 3.14 1.12
AA681520 57441 Geminin (Gmnn) 2.79 2.60 1.07 a
J04620 19075 DNA primase, p49 subunit (Prim1)z 2.63 1.33 1.98 a c,d,f,g
AF036898 18974 DNA polymerase epsilon, subunit 2 (Pole2) 2.55 1.97 1.29
M13352 22171 Thymidylate synthase (Tyms, TS)z 2.35 2.70 1.15 a f
X77731 13178 Deoxycytidine kinase (Dck) 2.32 2.22 1.05 b
X75483 12428 Cyclin A2 (Ccna2) 2.23 2.51 1.13 a c,g c,i,j
X60980 21877 Thymidine kinase 1 (Tk1) 2.23 2.38 1.07 a c,d,g
AU044050 22171 Thymidylate synthase (Tyms, TS)z 2.15 2.37 1.10 a c
AB025409 54124 CDC28 protein kinase 1 (Cks1) 2.14 2.34 1.09 g i,j
X16495 Histone H2A 1.67 2.63 1.57
K02245 18811 Proliferinz 1.08 4.01 4.33
(B) Mitosis/cell division (19 unique transcripts)
U01063 18817 Polo-like kinase homolog (Plk1)z 6.20 6.79 1.10 a g c,i,j
X82786 17345 Antigen identified by monoclonal antibody Ki 67z 6.01 7.53 1.25 a f,g,c c,i
X64713 12429 Cyclin B1, related sequence 1 (Ccnb1-rs1, CycB1)z 5.82 5.94 1.02 a c,d c,i,j
AB013819 11799 Baculoviral IAP repeat-containing 5 (Survivin) 5.66 9.68 1.71
L11316 13605 Epithelial cell – transforming sequence (ect) 2 oncogene 5.60 4.40 1.27 c
AF002823 12235 Budding uninhibited by benz-1 homolog (Bub1a) 4.53 5.39 1.19 a c,d
X66032 12442 Cyclin B2 (Ccnb2, Cycb2)z 4.46 5.33 1.20 a c
AV309347 17345 Antigen identified by monoclonal antibody Ki 67z 4.35 7.47 1.72 a c,f,g c,i
Y09632 19348 Rab6, kinesin-like (Rab6kifl) 4.29 6.04 1.41 c
U80932 20878 Serine/threonine kinase 6 (Stk6, Ark1, Ayk1) 4.17 4.47 1.07 c
D21099 20877 Serine/threonine kinase 5 (Stk5, Aim1, Stk-1) 3.90 4.99 1.28 d,f c
AW061324 107995 Cell division cycle 20 homolog (Cdc20) 3.89 4.02 1.03 a c,i,j
AJ223293 16587 Kinesin-like 1 (Knsl1, Kif8, Kifl1) 3.70 5.35 1.45 a i,j
L29480 20873 Serine/threonine kinase 18 (Sak) 3.54 3.92 1.11 d,f
L16926 12532 Cell division cycle 25 homolog C (Cdc25c)z 3.43 3.85 1.12 c
D12646 16571 Kinesin heavy chain member 4 (Kif4, Kns4) 3.21 4.32 1.35 c
M38724 12534 Cell division cycle 2 homolog A (Cdc2a)z 3.18 3.28 1.03 a c,f,g c,i,j
U83902 56150 MAD2-like 1 (Mad2l1) 3.16 3.54 1.12 g
AF013166 18005 NIMA (never in mitosis gene a)– related kinase 2 (Nek2) 2.85 3.59 1.26 g i
AV059766 19348 Rab6, kinesin-like (Rab6kifl) 2.40 3.40 1.42 c
AA823653 16319 Inner centromere protein (Incenp) 2.28 3.02 1.32 a
(C) Miscellaneous cell cycle – related genes (three unique transcripts)
AW209238 21335 Transforming, acidic coiled coil containing protein 3 4.11 5.47 1.33
AF062378 12316 Calmodulin binding protein 1 (Calmbp1, Sha1) 2.40 3.50 1.46
D87326 14841 Germ cell –specific gene 2 (Gsg2, Haspin) 2.13 2.25 1.06
Transcription/chromatin structure/DNA repair (eight unique transcripts)
X67668 15352 High-mobility group box 2 (Hmgb2) 4.13 2.74 1.51 a,b c,f c
U25691 15201 Helicase, lymphoid-specific (Hells) 3.39 2.17 1.56
U52951 14056 Enhancer of zeste homolog 2 (Ezh2) 2.63 1.82 1.45 a,b c,d,e
D13803 19361 RAD51 homolog (Rad51) 2.40 3.09 1.29 a c,d,g,h c
AA896295 60411 SoxLZ/Sox6 leucine zipper binding
protein in testis
2.33 2.37 1.02
AI852641 56312 Nuclear protein 1 (Nupr1, p8)z 1.20 2.88 2.40
X67083 13198 DNA damage-inducible transcript 3
(Ddit3, Gadd153)
2.19 2.54 1.16
V00727 14281 FBJ osteosarcoma oncogene (c-Fos)z 3.25 1.39 2.34
(continued on next page)
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Table 1. (continued )
Accession Locus
Link
Gene wtT/wtU* KOT/KOU Fold
Change
Repressed
by p16/pRby
Bound or
Regulated
by E2Fs
Cell
Cycle–
Regulated
Signal transduction (four unique transcripts)
U94828 19734 Regulator of G-protein signaling 16 (Rgs16) 3.62 3.48 1.04
AV349152 19734 Regulator of G-protein signaling 16 (Rgs16) 3.25 4.07 1.25
M90388 19260 Protein tyrosine phosphatase, nonreceptor type 8 2.42 1.22 1.98
M32490 16007 Cysteine-rich protein 61 (Cyr61) 1.50 2.83 1.89
AF031127 inositol trisphosphate receptor type 2 1.77 2.26 1.28
Cytoskeleton/adhesion/extracellular matrix/cell – cell signaling (four unique transcripts)
AF072127 12737 Claudin 1 (Cldn1)z 3.04 3.09 1.02
AV230686 21923 Tenascin C (Tnc)z 2.37 5.42 2.29
U52524 15117 Hyaluronan synthase 2 (Has2) 1.77 2.60 1.47 i
X56304 21923 Tenascin C (Tnc)z 1.18 4.56 3.86
M81445 14619 Gap junction membrane channel
protein beta 2 (Gjb2)
2.01 2.64 1.31
Immune response (seven unique transcripts)
X04653 110454 Lymphocyte antigen 6 complex, locus A (Ly6a) 2.54 1.38 1.84
AF022371 15950 Interferon-activated gene 203 (Ifi203)z 1.26 2.59 2.06
Y07812 17153 mal, T cell differentiation protein (Mal, Mpv17) 1.51 2.58 1.71
AF000236 12778 Chemokine orphan receptor 1 (Cmkor1, Rdc1) 2.45 2.43 1.01 d
Y00629 15040 Histocompatibility 2, T region locus 23 (H2-T23) 2.45 2.85 1.16 d
AF068182 17060 Lymphocyte antigen 57 (B-cell linker, Blnk) 2.87 1.34 2.14
AF068182 17060 Lymphocyte antigen 57 (B-cell linker, Blnk) 2.89 1.57 1.84
AC002397 12034 B-cell receptor–associated protein 37 2.91 1.62 1.80
Fatty acid metabolism (three unique transcripts)
M21285 20249 Stearoyl-coenzyme A desaturase 1 (Scd1) 3.86 1.66 2.33
M21285 20249 Stearoyl-coenzyme A desaturase 1 (Scd1) 2.63 1.46 1.80
AJ223066 16592 Fatty acid binding protein 5, epidermal (Fabp5) 2.13 2.49 1.17
AF017175 12894 Carnitine palmitoyltransferase 1, liver (Cpt1a) 1.97 2.70 1.37 i
Miscellaneous (19 unique transcripts)
Z29532 14313 Follistatin (Fst)z 5.16 2.09 2.47 b e
AI047076 60530 Fidgetin-like 1 (Fignl1) 4.20 3.00 1.40
AI852645 69716 Thyroid hormone-R interactor 13 (Trip13) 3.76 5.03 1.34
U42385 14211 Fibroblast growth factor – inducible 16 (Fin16) 3.38 3.65 1.08 c,d
D55720 16647 Karyopherin (importin) alpha 2 (Kpna2) 3.37 2.94 1.15 c,i,j
AA032310 22695 Zinc finger protein 36 (Zfp36, tristetraprolin) 3.22 3.03 1.06
AW227345 57806 U2 small nuclear ribonucleoprotein polypeptide AV 2.93 2.03 1.44
AI838853 56207 Ubiquitin carboxyl-terminal esterase L5 (Uchl5) 2.63 2.34 1.12
AA913994 20425 Serine hydroxymethyl transferase 1 (Shmt1) 2.52 1.89 1.33
AF058055 20501 Solute carrier family 16, member 1 (Slc16a1) 2.46 1.95 1.26
AF103875 26357 ATP-binding cassette, subfamily G, member 2 2.19 2.69 1.23
AJ002390 11752 Annexin A8 (Anxa8) 1.34 3.46 2.58 c,d
AI840339 58809 Ribonuclease, RNase A family 4 (Rnase4) 1.42 2.39 1.68
U60593 17988 N-myc downstream– regulated 1 (Ndr1) 1.62 2.53 1.56 i,j
AI839138 56338 Thioredoxin-interacting protein (Txnip) 1.64 3.20 1.95
M32017 16784 Lysosomal membrane glycoprotein 2 (Lamp2) 1.89 2.39 1.26
U52073 17990 N-myc downstream– regulated– like (Ndrl, Tdd5) 1.97 2.70 1.37 d
AI853960 67183 Ribosomal protein L22 (Rpl22) 1.98 2.43 1.23
AW124337 56615 Microsomal glutathione S-transferase 1 (Mgst1) 2.34 6.29 2.69
Genes of undefined function (34 unique transcripts)
AA184423 73644 2210039B01Rik: unknown 5.84 2.26 2.58
AA590345 106108 EST AA408511: unknown 5.45 6.30 1.16
AW259499 101449 EST AA410048: unknown 4.83 3.46 1.40
AW123269 97521 EST C78101: similar to anillin, actin-binding prtn 4.58 4.58 1.00 a g
AI122538 68026 2810417H13Rik: 93% similar to pyrimidine binding prtn 2 4.56 6.48 1.42
AI848479 73644 2210039B01Rik: unknown 4.45 2.01 2.21
AA822539 73644 2210039B01Rik: unknown 3.88 1.17 4.54
AI595322 EST: 94% similar to retinoblastoma-associated Hec1 3.74 4.45 1.19 c,g
AA681998 66197 1110038L14Rik: 94% CDC28 prtn kinase 2 (CKS2) 3.66 3.66 1.00 a
AI131895 101761 EST AU021460: similar to kinesin-like 4 (KID) 3.45 4.32 1.25 a g i
AA989957 67196 2700084L22Rik: similar to ubiquitin-conjugating enzyme 3.36 2.58 1.30 g c,i
AA856349 52439 D7Ertd348e: similar to prtn regulator of cytokinesis 1 3.29 4.65 1.41 a g
AI852985 69071 1810014L12Rik: unknown 3.17 2.69 1.18
AV228594 EST: similar to D.m. barren (mitosis) 3.17 2.68 1.18
AW060793 98772 EST: 87% R.n. ADP-ribosylation factor – like prtn 5 3.01 1.35 2.23
(continued on next page)
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Table 1. (continued )
Accession Locus
Link
Gene wtT/wtU* KOT/KOU Fold
Change
Repressed
by p16/pRby
Bound or
Regulated
by E2Fs
Cell
Cycle–
Regulated
AI510131 30866 EST: 98% M.m. hepatoma upregulated protein 2.92 2.83 1.03
AI851230 66949 2310035M22Rik: unknown 2.89 2.38 1.21
AA275196 99457 EST: 100% similar to M.m. nucleolar protein ANKT 2.84 4.54 1.60
AW122331 68105 4831429J16Rik: unknown 2.75 3.22 1.17
AI197337 52089 D4Ertd27e: unknown 2.71 2.39 1.13
AI462312 EST: unknown 2.70 2.88 1.07
AI843655 102464 EST AI256758: similar to H.s. topoisomerase (DNA) II bp 2.65 1.64 1.62
AW213883 EST: 98% similar to similar to barr-P1 (D.m. barren) 2.57 2.62 1.02
AI848382 EST: similar to M.m. ubiquitin-specific protease 2.56 1.84 1.39 a
AW213865 66929 1700003K02Rik: unknown 2.53 3.15 1.25
AA007891 73804 4930402F02Rik: similar to mitotic centromere–associated kinesin 2.50 3.05 1.22
AW214617 70385 2600001J17Rik: unknown 2.44 3.05 1.25
AW229141 69482 2310006I24Rik: 97% similar to mitotic phosphoprotein 44 2.40 2.65 1.10
AA409629 102848 EST: 93% similar to R.n. polypyrimidine tract binding prtn 2.38 3.19 1.34
AA716963 EST: similar to isopentenyl-diphosphate delta isomerase 2.37 3.22 1.36
AI850288 71747 1300002E07Rik: unknown 2.34 2.93 1.25
AI591702 97568 EST C87313: unknown 2.27 3.27 1.44
AI846439 66578 2610039C10Rik: unknown 2.21 2.31 1.05
AA914734 27985 D4Wsu24e: unknown 1.69 2.62 1.55
AW124049 52331 D5Ertd593e: unknown 2.04 2.76 1.35
AI043040 98264 EST AI118496: 99% similar to M.m. polyductin (Pkhd1) 2.25 1.12 2.01
AA755260 EST: 100% similar to deleted in polyposis 1-like 1 2.64 3.16 1.20
*Responses of wild-type (wt) and Rb knockout (KO) prostate epithelial cells to 48-hour culture in serum-free conditions are represented by the ratio of average
signal from treated (T) to untreated (U) samples. Fold changes for each transcript between wtPrE and Rb/PrE were calculated by dividing wt and KO ratios.
yGenes that have been previously described as being repressed by p16ink4a or pRb [(a) Ref. [44]; (b) Ref. [46]], bound or regulated by E2Fs [(c) Ref. [38]; (d) Ref.
[43]; (e) Ref. [45]; (f) Ref. [16]; (g) Ref. [17]; (h) Ref. [47]], or cell cycle – regulated [(i) Ref. [37]; (j) Ref. [38]; (j) Ref. [39]].
zRepresent genes confirmed by semiquantitative RT-PCR.
Figure 2. Comparison of gene expression profiles of growth-arrested Rb+/+ and Rb/ cell lines. Gene expression alterations in response to serum withdrawal in
Rb+/+ cell lines were plotted along the x-axis, and gene expression alteration in response to serum withdrawal in Rb/ cell lines was plotted along the y-axis. The
dashed line represents a 1:1 correlation between wild-type cell line fold change and Rb/PrE cell line fold change. Shaded areas represent the limits of the two-
fold change between the two cell lines. Each filled circle represents the combined wild-type and Rb/PrE cell line data for an individual gene transcript.
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difference (annexin A8 [2.58]; Mcmd [2.64]; Mgst1 [2.69];
tenascin C [3.86]; proliferin [4.33]; and 2210039B01Rik
[4.54]; Table 1). These highly conserved gene expression
profiles between wild-type and Rb/ cells suggested that
pRb was not required for the vast majority of gene expres-
sion alterations associated with growth arrest in murine
prostate epithelial cells.
Validation of Gene Expression in Both wtPrE and
Rb/ PrE Cells
To confirm gene expression alterations observed with the
Affymetrix GeneChips, we performed semiquantitative RT-
PCR for several randomly selected transcripts from each of
the main functional clusters of genes. Total RNA was iso-
lated in triplicate from three independently derived wtPrE or
Rb/PrE cell lines under log-phase or growth-arrested con-
ditions, and RT-PCR was performed with primers specific to
each transcript. To assure that amplification was within a
linear range when analyzed, samples were removed from
each reaction following cycles 25, 28, 31, and 34, consistent
with other previously reported methods [40]. Results of the
semiquantitative RT-PCR experiments (Figures 3, 4, and 5)
correlated closely with those obtained from the microarray
experiments (Table 1). When several genes from the G1/S
cluster were analyzed, all transcripts exhibited downregula-
tion following growth arrest similar to that identified in
the microarray analysis. Ribonucleotide reductase M2
(Rrm2), myeloblastosis oncogene (c-Myb), minichromosome
maintenance–deficient (Mcmd/Mcm3), flap structure endo-
nuclease 1 (Fen1), DNA primase p49 (Prim1), and thymidy-
late synthase (Tyms) were all considerably downregulated in
both wtPrE and Rb/PrE compared to the hypoxanthine
guanine phosphoribosyl transferase (HPRT) control transcript
(Figure 3). Interestingly, Mcmd, which appeared from the
microarray results to be differentially regulated between the
wild-type and Rb/PrE cell lines, was not observed to be
more strongly downregulated in the wtPrE by semiquantita-
tive RT-PCR in four replicate studies (Figure 3; data not
shown). These findings suggest that if differences exist
between wild-type and Rb/ prostate epithelial cells, they
may be even more conservative than suggested by micro-
array analysis.
Validation of genes in the G2/M functional cluster was
performed in an identical fashion as described above. As
indicated in Figure 4, total RNA was isolated from log-phase
or growth-arrested wtPrE and Rb/PrE and semiquantita-
tive RT-PCR was performed for polo-like kinase homolog
(Plk1), Ki67, cyclin B1-related sequence 1 (Ccnb1-rs1), cyclin
B2 (Cycb2), cell division cycle 25 homolog c (Cdc25c), and
Figure 3. Semiquantitative RT-PCR confirmation of G1/S phase genes
repressed following growth arrest. wtPrE and Rb/PrE cells were cultured in
the presence or absence of serum for 48 hours. Equal cDNA generated from
total RNA was utilized in RT-PCR reactions with primers specific to Rrm2, c-
Myb, Mcmd, Fen1, Prim1, or Tyms. The HPRT transcript is a housekeeping
gene that serves as a loading control. Only the reactions that best
represented the linear range of amplification are depicted.
Figure 4. Semiquantitative RT-PCR confirmation of G2/M phase genes
repressed following growth arrest. wtPrE and Rb/PrE cells were cultured in
the presence or absence of serum for 48 hours. Equal cDNA generated from
total RNA was utilized in RT-PCR reactions with primers specific to Plk1,
Ki67, Ccnb1rs1, Cycb2, Cdc25c, or Cdc2a. The actin transcript serves as a
loading control.
Figure 5. Semiquantitative RT-PCR confirmation of genes identified by mi-
croarray analysis as being differentially regulated between wtPrE and Rb/PrE
during growth arrest. wtPrE and Rb/PrE cells were cultured in the presence
or absence of serum for 48 hours. Equal cDNA generated from total RNA was
utilized in RT-PCR reactions with primers specific to proliferin or Ifi203. The
actin transcript serves as a loading control.
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Cdc2a. Semiquantitative RT-PCR results correlated precisely
with microarray results, suggesting that little difference exists
between the ability of Rb+/+ and Rb/ cells to repress
transcription of genes involved in G2/M phase functions
following growth arrest. These data demonstrate that overall
gene expression changes following growth arrest are nearly
identical in prostate epithelial cells independent of pRb status.
Finally, due to the potential for random variation and
nonspecific hybridization intrinsic to such large-scale micro-
array studies, six transcripts were selected from the 14 genes
identified as being differentially regulated to determine
whether these genes were also differentially regulated when
assessed by semiquantitative RT-PCR. For this analysis,
semiquantitative RT-PCR was performed for tenascin C
(Tnc), follistatin (Fst), interferon-activated gene 203 (Ifi203),
FBJ osteosarcoma oncogene (c-Fos), proliferin (Plf), and
nuclear protein 1 (Nupr1; Figure 5). Triplicate analysis of
mRNA levels for these genes in three Rb+/+ and Rb/
prostate epithelial cell lines indicated that differences ob-
served in the microarray experiments for Tnc, Fst, c-Fos, and
Nupr1 did not exist when analyzed by RT-PCR. Tnc and Fst
were both strongly downregulated and Nupr1 was upregu-
lated following growth arrest of prostate epithelial cell lines
independent of pRb status (data not shown). On the other
hand, semiquantitative RT-PCR confirmed gene expression
differences between Rb+/+ and Rb/ cell lines for Ifi203
and proliferin (Figure 5). Ifi203 was repeatedly upregulated
several-fold in growth-arrested compared to log-phase
Rb/PrE cells, but this was not observed in the wtPrE cells.
Additionally, proliferin was downregulated in growth-arrested
Rb/PrE cells, but not in wtPrE cells. Therefore, the Ifi203
and proliferin transcripts were confirmed to exhibit altered
regulation in Rb/PrE following growth arrest. Additional
research will be required to determine the role of these
alterations in the susceptibility of Rb/ prostate tissue to
tumorigenesis.
Discussion
In an effort to identify any unique functions contributed by
pRb in the regulation of cell cycle and growth arrest, we have
analyzed the gene expression profiles of three independently
established Rb+/+ and Rb/ prostate epithelial cell lines
under log-phase or growth-arrested conditions. Considering
the role of pRb as a tumor-suppressor gene and a purported
major regulator of the G1/S phase transition, it was surprising
that both wild-type and Rb/ prostate epithelium proliferated
with identical kinetics and growth-arrested similarly in re-
sponse to short-term serum withdrawal. Additionally, when
Affymetrix gene expression analysis was performed on these
two cell lines, it was unanticipated that among all the genes
identified as being altered in response to growth arrest
conditions, only 14 of these exhibited a z2.0-fold difference
in response between the Rb+/+ and Rb/ cell lines. These
findings demonstrate that in the absence of pRb, prostate
epithelial cells retain the ability to perform functions previ-
ously associated with pRb, including growth arresting under
serum-free culture conditions and inhibiting transcription of
genes involved in several cellular processes including DNA
replication and G2/M phase regulation.
pRb Is Not Strictly Required for G1 Growth Arrest
Studies from our group and others have now demonstrated
that MEFs and prostate epithelial cells lacking pRb as a
result of homologous recombination retain the ability to
growth-arrest in the G1 phase of the cell cycle in vitro
[31,32,34]. These findings suggest that mechanisms other
than those involving pRb exist to induce growth arrest when
pRb is genetically inactivated. Current data support an
underlying role for the remaining pocket protein family mem-
bers, p107 and p130, in this compensatory growth arrest
mechanism [31,32]. Studies in which the individual pocket
proteins were inactivated revealed that loss of pRb, p107, or
p130 alone had no major impact on cell cycle profile, rate of
immortalization, growth in soft agar, or tumorigenicity in
immune-compromised mice [31,32]. Yet, when the effects
of various combinations of pocket protein deletions were
studied, it became clear that a triple knockout of the entire
pocket protein family (Rb/p107/p130/) was required
to obtain convincing loss of the G1 growth arrest function
and increased susceptibility to immortalization [31,32]. The
results of these cellular studies are also supported by
biochemical data. For example, in normal Rb+/+ neural
precursor cells, pRb is found complexed primarily with
E2F3, whereas p107 and p130 interact primarily with E2F4
and E2F5 [41]. However, in neural precursor cells isolated
from Rb/ mice, p107 was upregulated and was uncharac-
teristically found interacting with E2F3 [41]. These data
reveal a compensatory mechanism whereby the loss of
one pocket protein is balanced by the upregulation of the
remaining pocket proteins and interactions of these remain-
ing proteins with additional E2Fs normally regulated by the
lost pocket protein. Therefore, the increased levels of p107
observed in our Rb/ prostate epithelial cell lines and the
potential interaction of p107 with the activating E2Fs may
result in normal growth kinetics and growth arrest following
serum depletion despite the lack of pRb.
Perhaps complicating these initial findings are recent
results from Sage et al. [42], who utilized a conditional allele
of the Rb gene (cRb), which allowed for acute deletion of Rb
when cRblox/lox MEFs were infected with an adenovirus
vector expressing the Cre recombinase gene to generate
cRb/ cells. In these experiments, acute loss of pRb was
sufficient to induce cell cycle reentry in quiescent or senes-
cent MEFs, suggesting that pRb is normally required for
maintenance of the growth-arrested phenotype [42]. How-
ever, through the use of siRNA-based knockdown experi-
ments, this group also demonstrated that if the elevated
p107 levels in growth-arrested Rb/ MEFs were decreased,
these cells reentered the cell cycle as measured by BrdU
incorporation [42]. Therefore, these data are in agreement
with our findings that prostate epithelial cells that constitutively
lack pRb due to homologous recombination maintain the
ability to growth-arrest due to pocket protein compensatory
mechanisms, yet they also raise useful questions as to which
model will be more informative for cancer research. Perhaps
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in the end, it will be determined that both models will be of use
as even the acutely deleted cRb/ MEFs compensated for
pRb loss by upregulating p107 within 2 days of Rb deletion
and some of these cultures eventually reentered senescence
approximately 10 passages following acute Rb deletion [42].
Regulation of E2F Target Genes in the Absence of pRb
Microarray-based and chromatin immunoprecipitation-
based analyses have recently been used by several groups
to identify large numbers of genes targeted by specific
transcription factors including pRb and the E2F family
[16,17,38,43–47]. The majority of these studies has helped
to identify genes that were regulated by ectopic expression of
various E2Fs or a constitutively active (phosphorylation sites
mutated; PSM-Rb) pRb. As denoted in Table 1, our study
demonstrated thatRb/ prostate epithelial cells retained the
ability to transcriptionally regulate 97% (30/31) and 93%
(37/40) of the PSM-Rb and E2F target genes, respectively,
that were altered in the growth-arrested wild-type cells.
These findings demonstrate that although a constitutively
active pRb has the ability to repress these genes in an
inducible Rat-16 fibroblast model system [44], pRb is not
the only protein capable of regulating these genes under
growth-arrested conditions. In agreement with our findings,
Hurford et al. [48] demonstrated that Rb/ MEFs exhibited
derepressed expression in G0/G1 of only 2 of 21 E2F-
regulated genes tested by Northern blot. Taking into account
the aforementioned findings of several groups, the most
likely explanation for our observation is functional compen-
sation for pRb loss by p107 and possibly p130.
Recently, Black et al. [49] utilized microarray to analyze
the gene expression phenotypes of wild-type, Rb/, and
p107/p130/ MEFs grown under serum-starved (0.25%
FBS) conditions. The goal of their experiments was similar to
ours in that they aimed to obtain a global evaluation of the
gene expression alterations coinciding with the loss of the
pocket protein family members. Intriguingly, the results of
their studies in a MEF system differed greatly from those of
differentiated prostate epithelial cells. In their study, Rb/
MEFs exhibited greatly elevated levels (in many cases 10- to
20-fold increases) of many E2F target genes [49]. However,
6 and 29 of the 100 genes identified in their study were also
investigated either by Hurford et al. [48] or our group,
respectively, and were not found to be responding differently
based on Rb genotype. The differing results may be due to
the use of different model systems (MEFs versus prostate
epithelial cells), or due to an earlier analysis of gene expres-
sion in the MEF study compared to ours (passage 4 MEFs
versus passage 15 prostate epithelial cells); however, these
differences cannot explain the differences between the Hur-
ford and Nevins studies. Further investigation of these differ-
ences may provide information on the tissue-specific role of
pRb in regulating E2F-mediated gene expression.
Although the results of our study demonstrate a nones-
sential role for pRb in the regulation of growth arrest in an
epithelial cell line constitutively lacking Rb, we do not sug-
gest that pRb only plays redundant roles simultaneously
regulated by the other pocket proteins. The goal of this study
was to understand the molecular response ofRb+/+ andRb/
cells to serum depletion–induced growth arrest, and does not
measure the ability of pRb to perform other functions including
regulation of differentiation or cooperative activation of tran-
scription by certain non-E2F transcription factors. This is an
important clarification as the ability of pRb to induce growth
arrest and repress E2F-mediated transcription is separable
from the ability of pRb to induce flat cell morphologies,
differentiation, and cooperative transcriptional activation with
tissue-specific transcription factors involved in differentiation
[50]. Clearly, an important role for pRb regulation of E2F1
in development has already been established genetically
as homozygous mutation of E2F1 in Rb/ and Rb+/ mice
decreased the severity of their respective phenotypes [51,52].
Additionally, pRb may be involved in posttranslational regula-
tion of proteins involved in cell cycle arrest and other cellular
processes not identified by microarray studies that focus
solely on transcriptional regulation.
In summary, we have generated a gene expression
profile of Rb+/+ and Rb/ prostate epithelial cells as they
respond to serum removal and growth arrest. Surprisingly,
very minor differences were observed in the ability of these
two cell lines to repress the same set of growth-regulated
genes. Among the genes that are equivalently regulated
between the two cell lines are many E2F targets. Current
data would suggest that in the Rb/ cells, the regulation of
E2F target genes is occurring through direct functional com-
pensation by p107. Further studies to assess novel interac-
tions between p107 and/or p130 and E2Fs 1–3 in the Rb/
prostate epithelial cells are required to provide further clarity
to this proposal.
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